Kezar Life Sciences (KZR) Equity Average (2021 - 2025)
Historic Equity Average for Kezar Life Sciences (KZR) over the last 5 years, with Q3 2025 value amounting to $87.4 million.
- Kezar Life Sciences' Equity Average fell 3862.27% to $87.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.4 million, marking a year-over-year decrease of 3862.27%. This contributed to the annual value of $152.2 million for FY2024, which is 3343.72% down from last year.
- Kezar Life Sciences' Equity Average amounted to $87.4 million in Q3 2025, which was down 3862.27% from $97.4 million recorded in Q2 2025.
- In the past 5 years, Kezar Life Sciences' Equity Average registered a high of $290.3 million during Q3 2022, and its lowest value of $87.4 million during Q3 2025.
- Moreover, its 5-year median value for Equity Average was $169.1 million (2024), whereas its average is $183.0 million.
- Per our database at Business Quant, Kezar Life Sciences' Equity Average skyrocketed by 13281.03% in 2022 and then tumbled by 3907.09% in 2025.
- Over the past 5 years, Kezar Life Sciences' Equity Average (Quarter) stood at $158.2 million in 2021, then skyrocketed by 74.82% to $276.5 million in 2022, then decreased by 27.03% to $201.8 million in 2023, then tumbled by 37.81% to $125.5 million in 2024, then crashed by 30.36% to $87.4 million in 2025.
- Its last three reported values are $87.4 million in Q3 2025, $97.4 million for Q2 2025, and $110.0 million during Q1 2025.